Multiple System Atrophy (MSA) remains one of the most challenging neurodegenerative disorders to treat. The multi-system involvement and rapid progression demand a comprehensive approach combining symptomatic management, supportive care, and emerging disease-modifying strategies. This page reviews current treatment paradigms and promising therapeutic avenues.
MSA is a progressive neurodegenerative disorder characterized by autonomic failure in combination with parkinsonian or cerebellar features. The disease is classified into two main subtypes: MSA-P (predominant parkinsonism) and MSA-C (predominant cerebellar ataxia) . Pathologically, MSA is defined by the presence of glial cytoplasmic inclusions (GCIs) composed of aggregated α-synuclein within oligodendrocytes, which distinguishes it from Parkinson's disease where Lewy bodies primarily affect neurons .
The underlying pathogenesis involves a complex interplay between α-synuclein pathology, oligodendrocyte dysfunction, and neuronal degeneration . The selective vulnerability of oligodendrocytes in MSA makes it unique among α-synucleinopathies, as these myelin-producing cells fail to properly support neurons, leading to widespread white matter dysfunction and progressive neurological decline.
¶ Clinical Features and Natural History
MSA typically presents in the sixth decade of life with a median survival of 6-10 years from symptom onset . The rapid progression distinguishes MSA from Parkinson's disease, where patients may maintain function for decades. Early autonomic dysfunction—including orthostatic hypotension, urinary urgency, and REM sleep behavior disorder—often precedes motor symptoms by years.
| Disease Stage |
Typical Features |
Median Time from Onset |
| Prodromal |
RBD, OH, urinary symptoms |
0-2 years |
| Early |
Motor symptoms, autonomic dysfunction |
2-4 years |
| Mid |
Disability, fall risk |
4-6 years |
| Advanced |
Severe disability, dysphagia |
6-8 years |
Parkinsonian Features (MSA-P):
- Bradykinesia with rigidity
- Resting tremor (less common than PD)
- Poor levodopa response
- Early postural instability
Cerebellar Features (MSA-C):
- Gait ataxia with wide-based stance
- Limb dysmetria
- Scanning speech
- Oculomotor abnormalities
Levodopa/Carbidopa:
- Efficacy: Modest benefit in ~30% of patients
- Response pattern: Often transient (months), rarely sustained
- Dose: Up to 1000 mg/day (often poorly tolerated)
- Side effects: Orthostatic hypotension, confusion, hallucinations
- Note: Poor response helps distinguish from PD
Dopamine Agonists:
- Pramipexole, ropinirole, rotigotine
- Limited efficacy in MSA
- Often poorly tolerated due to orthostatic hypotension
Other Agents:
- Amantadine: May provide modest benefit for some patients
- Zonisamide: Limited evidence, not recommended
- Botulinum toxin: For cervical dystonia when present
Orthostatic Hypotension:
Orthostatic hypotension represents one of the most debilitating symptoms in MSA, affecting over 70% of patients . The pathophysiology involves failure of sympathetic baroreflexes, leading to inadequate vasoconstriction upon standing.
| Treatment |
Mechanism |
Dose |
Notes |
| Midodrine |
α1-adrenergic agonist |
5-10 mg TID |
Monitor supine hypertension |
| Droxidopa |
Norepinephrine prodrug |
100-600 mg TID |
FDA approved for OH |
| Fludrocortisone |
Mineralocorticoid |
0.1-0.3 mg daily |
Monitor fluid retention |
| Pyridostigmine |
Acetylcholinesterase |
30-60 mg TID |
Adjunct therapy |
| Compression stockings |
External compression |
Full leg |
Practical but limited |
Supine Hypertension:
- Nighttime head elevation (30°)
- Evening dose reduction of midodrine/droxidopa
- Consider short-acting antihypertensives if severe
- Clonidine patch may help manage nocturnal hypertension
Urinary Dysfunction:
Urinary symptoms in MSA reflect both detrusor overactivity and impaired sphincter control:
- Oxybutynin: Anticholinergic for detrusor overactivity
- Tamsulosin: α-blocker for outlet obstruction (if applicable)
- Intermittent catheterization for retention
- Desmopressin: For nocturnal polyuria (use with caution)
Sexual Dysfunction:
- PDE5 inhibitors may help erectile dysfunction
- Referral to sexual health specialist for comprehensive management
Sleep disturbances are extremely common in MSA and often precede motor symptoms :
REM Sleep Behavior Disorder:
- Clonazepam: 0.25-1.0 mg at bedtime
- Melatonin: 3-12 mg at bedtime
- Safety measures: Bed padding, remove sharp objects
Sleep-Apnea:
- CPAP titration if obstructive
- Monitoring for central sleep apnea (more common in MSA)
- Positional therapy may help
Nocturnal Stridor:
- Monitor for stridor during sleep
- May require tracheostomy in severe cases
- ENT evaluation for airway assessment
flowchart TD
subgraph MSA Treatment Targets
A["Motor Symptoms"] --> A1["Dopaminergic"]
B["Autonomic"] --> B1["Orthostatic"]
B --> B2["Urinary"]
B --> B3["Sexual"]
C["Sleep"] --> C1["RBD"]
C --> C2["Apnea"]
C --> C3["Stridor"]
end
subgraph Current Approaches
A1 --> D["Levodopa trial"]
A1 --> E["Dopamine agonists"]
B1 --> F["Midodrine/Droxidopa"]
B2 --> G["Anticholinergics"]
B3 --> H["PDE5 inhibitors"]
C1 --> I["Clonazepam/Melatonin"]
C2 --> J["CPAP"]
C3 --> K["Monitoring/Airway"]
end
Given MSA is an α-synucleinopathy, several approaches target pathological protein :
Immunotherapy:
- Active immunization: Vaccines targeting aggregated α-synuclein (e.g., Affitope PD01A)
- Passive immunization: Monoclonal antibodies (e.g., BLA1, PRX004, cinpanemab)
- Challenge: Limited penetration of blood-brain barrier, variable patient response
Aggregation Inhibitors:
- Small molecules preventing α-synuclein oligomerization
- NPT200-1, Anle138b in development
- Target early in disease course
RNA-Based Approaches:
- ASO targeting SNCA gene expression
- siRNA delivery to reduce α-synuclein production
- Gene therapy approaches
Cellular Protection:
- BDNF/GDNF: Promote neuron survival via neurotrophic factor delivery
- CoQ10: Mitochondrial support (mixed trial results)
- Vitamin D: Neuroprotective effects under investigation
Anti-inflammatory:
- Minocycline: Mixed results in clinical trials
- TNF-α inhibitors: Under exploration
- Microglial activation modulators
Unique to MSA as an oligodendrogliopathy :
- Remyelination strategies: Promote oligodendrocyte precursor cell differentiation
- Myelin stabilization: Prevent demyelination cascade
- Metabolic support: Enhance oligodendrocyte energy metabolism
- α-Synuclein clearance from oligodendrocytes: Target GCI formation
flowchart LR
Aα-Syn["Aα-Syn GCI Formation"] --> B["Oligodendrocyte Dysfunction"]
B --> C["Myelin Loss"]
C --> D["Axonal Degeneration"]
D --> E["Neuronal Death"]
F["Immunotherapy"] -.-> A
G["Remyelination"] -.-> C
H["Metabolic Support"] -.-> B
style A fill:#f3e5f5,stroke:#333
style B fill:#fff9c4,stroke:#333
style C fill:#fff3e0,stroke:#333
style D fill:#f66,stroke:#333
style E fill:#c00,stroke:#333,color:#fff
¶ Clinical Trial Landscape
| Agent |
Target |
Phase |
Status |
Notes |
| Cinpanemab |
α-syn |
Phase 2 |
Completed |
Biogen |
| Prasinezumab |
α-syn |
Phase 2 |
Completed |
Roche |
| UCB0599 |
α-syn oligomer |
Phase 2 |
Ongoing |
UCB |
| Aziravir |
Gene therapy |
Phase 1 |
Recruiting |
AAV vector |
| ND0612 |
Levodopa |
Phase 3 |
Ongoing |
Continuous infusion |
Understanding negative trials is critical for future development:
- Lithium: No benefit in Phase 2
- Riluzole: No disease modification
- Ivabradine: Failed for cardiovascular symptoms
- Minocycline: Negative in Phase 2/3
- CoQ10: Negative in large trial
Deep Brain Stimulation (DBS):
DBS has limited utility in MSA compared to Parkinson's disease :
- Target selection: Subthalamic nucleus (STN) or globus pallidus interna (GPi)
- Patient selection: Critical — only patients with good levodopa response considered
- Outcomes: More modest than in PD, variable results
- Risks: Higher complication rate due to autonomic dysfunction
- Considerations: Must rule out MSA before considering DBS
Infusion Therapies:
Continuous drug delivery systems under investigation:
- Levodopa-carbidopa intestinal gel (LCIG): Continuous duodenal infusion
- Apomorphine continuous subcutaneous infusion: For advanced motor symptoms
- Trial data: Limited in MSA population
Gene Therapy Strategies:
- AAV-mediated gene delivery: Targeting neurotrophic factors
- SNCA knockdown: Reducing alpha-synuclein expression
- Antisense oligonucleotide delivery: Direct brain administration
Cell-Based Therapies:
- Mesenchymal stem cells (MSCs): Neuroprotective potential
- Oligodendrocyte precursor cell transplantation: Remyelination approaches
- Neural stem cells: Replacement therapy
Novel Small Molecules:
- Autophagy enhancers: Rapamycin, trehalose
- Iron chelators: Deferoxamine, clioquinol
- Urate elevation: Neuroprotective approach
Accurate diagnosis and disease monitoring require biomarkers :
- Neuroimaging: MR planimetry, DTI, PET tracers
- Fluid biomarkers: Neurofilament light chain (NfL), α-synuclein SAA
- Neurophysiology: Skin biopsy for autonomic testing
¶ Supportive and Rehabilitation
- Balance training: Reduce fall risk
- Gait training: Improve mobility and prevent freezing
- Strength training: Maintain function and prevent sarcopenia
- Stretching: Manage contractures
- Aquatic therapy: Low-impact exercise option
¶ Speech and Swallowing
Speech and swallowing disorders affect over 90% of MSA patients:
- LSVT LOUD: Voice therapy for dysarthria
- Swallowing assessment: Video fluoroscopy
- Diet modification: Texture modifications as needed
- Lee Silverman Voice Treatment: May improve vocal loudness
- Home safety assessment
- Adaptive equipment
- Energy conservation techniques
- Wheelchair seating assessment
- Weight monitoring (unintended weight loss common)
- Dietary consultation for dysphagia
- Vitamin supplementation when needed
- Hydration management
flowchart TD
A["MSA Multidisciplinary Care"] --> B["Neurology"]
A --> C["Movement Disorders"]
A --> D["Physical Therapy"]
A --> E["Occupational Therapy"]
A --> F["Speech Pathology"]
A --> G["Nutrition"]
A --> H["Social Work"]
A --> I["Palliative Care"]
B --> J["Medication Management"]
C --> J
D --> K["Mobility Support"]
E --> K
F --> L["Communication"]
G --> M["Nutritional Status"]
H --> N["Support Services"]
I --> O["Quality of Life"]
- Dysphagia management: PEG tube consideration when oral intake inadequate
- Communication aids: Speech-generating devices for severe dysarthria
- Pain management: Neuropathic pain protocols
- Caregiver support: Respite care, support groups, education
- Advance care planning: Early discussion of care preferences
- Advance care directives
- Goals of care discussions
- Hospice involvement when appropriate
- Family support and counseling
- Symptom management at end of life
Immunotherapy approaches targeting pathological alpha-synuclein represent the most advanced disease-modifying strategy:
Active Immunization:
- ACI-35: Phosphoserine liposome-based vaccine (Phase 1/2)
- UB-311: Synthetic peptide vaccine (Phase 1)
- Generates antibodies against pathological alpha-synuclein
Passive Immunization:
- Pemiselimab (BIIB054): Anti-alpha-synuclein antibody (Phase 2)
- Lu AF87908: Antibody targeting aggregated alpha-synuclein (Phase 1)
- PRX004: Antibody targeting toxic oligomers (Phase 1)
Small molecules preventing alpha-synuclein aggregation:
| Agent |
Mechanism |
Development Stage |
| Anle138b |
Oligomer modulator |
Phase 1/2 |
| S-als3 |
RNAse inhibitor |
Preclinical |
| EGCG |
Aggregate binding |
Phase 2 |
| Curcumin |
Aggregate disruption |
Phase 2 |
Protecting and regenerating oligodendrocytes is central to MSA treatment:
Neurotrophic Factors:
- GDNF: Promotes oligodendrocyte survival (intraparenchymal delivery)
- BDNF: Supports myelination (AAV-mediated)
- CNTF: Protects against demyelination
Remyelination Strategies:
- ** Clemastine**: Promotes OPC differentiation (Phase 2)
- Anti-LINGO-1: Block inhibitory signaling (Phase 2)
- Retinoic acid: Enhances remyelination (Preclinical)
Viral vector delivery of therapeutic genes:
Gene Silencing:
- SNCA-targeted siRNA via AAV
- Antisense oligonucleotides (ASOs)
- CRISPR-based approaches
Enzyme Enhancement:
- GBA gene delivery for lysosomal function
- COQ2 for mitochondrial function
¶ Clinical Trial Landscape
Current therapeutic trials targeting various mechanisms:
| Trial |
Agent |
Mechanism |
Phase |
| NCT06035886 |
ABBV-0805 |
Alpha-synuclein antibody |
Phase 1 |
| NCT05307848 |
Masitinib |
CSF-1R inhibitor |
Phase 3 |
| NCT05423368 |
Ampreloxetine |
Norepinephrine reuptake |
Phase 3 |
| NCT05122091 |
CoQ10 |
Mitochondrial support |
Phase 2 |
Key obstacles to successful clinical trials include:
- Heterogeneous patient populations: Different subtypes may respond differently
- Limited understanding of disease stage: Intervention may be too late
- Lack of sensitive biomarkers: Difficult to measure disease progression
- BBB penetration: Many therapies cannot reach CNS targets
- Oligodendrocyte-specific targeting: Challenge to deliver therapy specifically
- Biomarker development: Earlier diagnosis through fluid and imaging biomarkers
- Genotype stratification: Personalized treatment based on genetic risk
- Stage-appropriate therapy: Match treatment to disease stage
- Subtype-specific interventions: MSA-P vs MSA-C targeting
- Multiple targets simultaneously (α-syn + oligodendrocyte + neuroinflammation)
- Symptomatic + disease-modifying approaches
- Sequential treatment approaches based on disease stage
- Multi-modal rehabilitation plus pharmacotherapy
- Disease modification through α-synuclein targeting
- Oligodendrocyte protection and remyelination
- Reliable biomarkers for diagnosis and trial endpoints
- Understanding prodromal phase for early intervention
- Personalized medicine approaches based on biomarker profiles
¶ Special Populations and Considerations
¶ Pediatric and Young-Onset MSA
While MSA predominantly affects adults in their sixth decade, rare cases of early-onset MSA require special consideration:
Clinical Presentation:
- More aggressive disease course
- Greater cerebellar involvement
- Potentially different treatment responses
Management Considerations:
- Aggressive symptomatic treatment
- Genetic counseling for family planning
- Long-term care planning
- Psychosocial support for young patients
Population-specific considerations affect treatment approaches:
European Populations:
- Higher prevalence of GBA variants
- Typical clinical presentation
East Asian Populations:
- Higher proportion of MSA-C subtype
- Different COQ2 variant frequencies
- Modified treatment responses observed
African Populations:
- Limited epidemiological data
- Need for population-specific studies
Understanding the cost-effectiveness of interventions informs healthcare resource allocation:
High-Cost Interventions:
- Deep brain stimulation: $50,000-150,000 procedure
- Continuous drug infusion systems: $100,000+ annually
- Gene therapy: Potentially one-time high cost
Symptomatic Management Costs:
- Annual medication costs: $5,000-20,000
- Assistive devices: $2,000-10,000
- Home care: $30,000-100,000 annually
Prioritizing interventions based on cost-effectiveness:
- Midodrine for orthostatic hypotension: Highly cost-effective
- Physical therapy: Excellent value for fall prevention
- Speech therapy: Moderate cost for significant benefit
- Experimental treatments: Variable, based on outcomes
Given the prominent mitochondrial dysfunction in MSA, targeting mitochondrial health represents a promising approach:
Coenzyme Q10:
- Electron transport chain support
- Phase 3 trials ongoing
- Potential benefit for carriers of COQ2 variants
Alpha-lipoic acid:
- Mitochondrial antioxidant
- Enhances insulin sensitivity
- Currently in preclinical evaluation
Mitochondrial agents:
- Mitochondrial division inhibitor (mdivi-1)
- PINK1 activators
- Autophagy enhancers targeting mitochondria
Iron dysregulation contributes to oligodendrocyte vulnerability:
Chelation Approaches:
- Deferoxamine: Limited CNS penetration
- Clioquinol: Better BBB penetration
- VK-28: Novel iron chelator
Clinical Trials:
- Phase 2 trials for neuroprotection
- Combination with antioxidants
Supporting neuronal and glial survival through neurotrophic factors:
Growth Factor Therapy:
- GDNF: Promotes oligodendrocyte survival
- BDNF: Supports neuronal health
- CNTF: Prevents demyelination
Delivery Methods:
- Intraparenchymal infusion
- AAV-mediated gene delivery
- Cell-based delivery systems
Comprehensive evaluation at diagnosis:
Baseline Testing:
- Neurological examination with UMSARS
- Autonomic function testing
- MRI brain with specific sequences
- CSF analysis for biomarkers
Multi-Disciplinary Referrals:
- Movement disorders neurology
- Autonomic specialist
- Physical therapy
- Speech pathology
- Social work
Regular assessment to track progression:
Scheduled Follow-up:
- 3-month intervals in first year
- 6-month intervals thereafter
- Annual comprehensive evaluation
Monitoring Parameters:
- Motor function (UMSARS)
- Autonomic symptoms
- Cognitive function
- Quality of life measures
Recognition and management of acute complications:
Autonomic Crises:
- Severe orthostatic hypotension
- Urinary retention
- Respiratory compromise
Neurological Crises:
- Falls with injury
- Dysphagia with aspiration
- Seizure activity
Progressive disease requires advance planning:
Caregiver Considerations:
- Family education and training
- Respite care planning
- Support group connections
- Financial planning
Facility Placement:
- When home care becomes insufficient
- Nursing facility selection
- Specialized dementia care if needed
Understanding alpha-synuclein transmission:
Mechanisms:
- Exosome-mediated transfer
- Direct cell-to-cell spread
- Template-driven aggregation
Therapeutic Implications:
- Blocking propagation pathways
- Early intervention strategies
- Targeting seeding activity
Cell replacement and regeneration:
Research Status:
- Preclinical safety established
- Efficacy being evaluated
- Manufacturing challenges remain
Cell Types:
- Embryonic stem cells
- Induced pluripotent stem cells
- Mesenchymal stem cells
Future clinical trials will increasingly use biomarkers:
Patient Selection:
- Genetic stratification (GBA, COQ2 carriers)
- Fluid biomarker enrichment
- Imaging marker selection
Endpoint Biomarkers:
- NfL for disease progression
- Alpha-synuclein seeding assays
- Imaging measures of response
Global efforts accelerate therapeutic development:
Consortia:
- MSA Coalition (United States)
- MSA Trust (United Kingdom)
- International MSA Working Group
- European Reference Networks
Shared Resources:
- Biobank repositories
- Clinical trial networks
- Registry databases
Treatment of MSA remains challenging due to poor understanding of disease mechanisms and limited therapeutic options. While current approaches focus on symptom management, the development of disease-modifying therapies targeting α-synuclein pathology and oligodendrocyte dysfunction offers hope for meaningful intervention. Comprehensive multidisciplinary care remains essential for optimizing quality of life in patients with MSA. Future success will depend on improved understanding of disease biology, development of reliable biomarkers, and implementation of precision medicine approaches tailored to individual patients.